In a report released today, Marc Frahm from Cowen & Co. reiterated a Buy rating on Magenta Therapeutics Inc (MGTA). The company’s shares opened today at $12.19.
According to TipRanks.com, Frahm is a 4-star analyst with an average return of 6.3% and a 57.4% success rate. Frahm covers the Healthcare sector, focusing on stocks such as Adaptimmune Therapeutics, Odonate Therapeutics Llc, and Applied Therapeutics Inc.
The word on The Street in general, suggests a Hold analyst consensus rating for Magenta Therapeutics Inc.
See today’s analyst top recommended stocks >>
Based on Magenta Therapeutics Inc’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $14.83 million. In comparison, last year the company had a GAAP net loss of $13.66 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Magenta Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of novel medicines for bone marrow transplants. It offers platform that focuses on critical areas of transplant medicine.